TY  - JOUR
AU  - Vučićević, Katarina
AU  - Jovanović, Marija
AU  - Golubović, Bojana
AU  - Vezmar-Kovačević, Sandra
AU  - Miljković, Branislava
AU  - Martinović, Žarko J.
AU  - Prostran, Milica
PY  - 2015
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/2408
AB  - The present study aimed to establish population pharmacokinetic model for phenobarbital (PB), examining and quantifying the magnitude of PB interactions with other antiepileptic drugs concomitantly used and to demonstrate its use for individualization of PB dosing regimen in adult epileptic patients. In total 205 PB concentrations were obtained during routine clinical monitoring of 136 adult epilepsy patients. PB steady state concentrations were measured by homogeneous enzyme immunoassay. Nonlinear mixed effects modelling (NONMEM) was applied for data analyses and evaluation of the final model. According to the final population model, significant determinant of apparent PB clearance (CL/F) was daily dose of concomitantly given valproic acid (VPA). Typical value of PB CL/F for final model was estimated at 0.314 l/h. Based on the final model, co-therapy with usual VPA dose of 1000 mg/day, resulted in PB CL/F average decrease of about 25 %, while 2000 mg/day leads to an average 50 % decrease in PB CL/F. Developed population PB model may be used in estimating individual CL/F for adult epileptic patients and could be applied for individualizing dosing regimen taking into account dose-dependent effect of concomitantly given VPA.
PB  - Springer Heidelberg, Heidelberg
T2  - European Journal of Clinical Pharmacology
T1  - Nonlinear mixed effects modelling approach in investigating phenobarbital pharmacokinetic interactions in epileptic patients
VL  - 71
IS  - 2
SP  - 183
EP  - 190
DO  - 10.1007/s00228-014-1778-7
ER  - 

@article{
author = "Vučićević, Katarina and Jovanović, Marija and Golubović, Bojana and Vezmar-Kovačević, Sandra and Miljković, Branislava and Martinović, Žarko J. and Prostran, Milica",
year = "2015",
abstract = "The present study aimed to establish population pharmacokinetic model for phenobarbital (PB), examining and quantifying the magnitude of PB interactions with other antiepileptic drugs concomitantly used and to demonstrate its use for individualization of PB dosing regimen in adult epileptic patients. In total 205 PB concentrations were obtained during routine clinical monitoring of 136 adult epilepsy patients. PB steady state concentrations were measured by homogeneous enzyme immunoassay. Nonlinear mixed effects modelling (NONMEM) was applied for data analyses and evaluation of the final model. According to the final population model, significant determinant of apparent PB clearance (CL/F) was daily dose of concomitantly given valproic acid (VPA). Typical value of PB CL/F for final model was estimated at 0.314 l/h. Based on the final model, co-therapy with usual VPA dose of 1000 mg/day, resulted in PB CL/F average decrease of about 25 %, while 2000 mg/day leads to an average 50 % decrease in PB CL/F. Developed population PB model may be used in estimating individual CL/F for adult epileptic patients and could be applied for individualizing dosing regimen taking into account dose-dependent effect of concomitantly given VPA.",
publisher = "Springer Heidelberg, Heidelberg",
journal = "European Journal of Clinical Pharmacology",
title = "Nonlinear mixed effects modelling approach in investigating phenobarbital pharmacokinetic interactions in epileptic patients",
volume = "71",
number = "2",
pages = "183-190",
doi = "10.1007/s00228-014-1778-7"
}

Vučićević, K., Jovanović, M., Golubović, B., Vezmar-Kovačević, S., Miljković, B., Martinović, Ž. J.,& Prostran, M.. (2015). Nonlinear mixed effects modelling approach in investigating phenobarbital pharmacokinetic interactions in epileptic patients. in European Journal of Clinical Pharmacology
Springer Heidelberg, Heidelberg., 71(2), 183-190.
https://doi.org/10.1007/s00228-014-1778-7

Vučićević K, Jovanović M, Golubović B, Vezmar-Kovačević S, Miljković B, Martinović ŽJ, Prostran M. Nonlinear mixed effects modelling approach in investigating phenobarbital pharmacokinetic interactions in epileptic patients. in European Journal of Clinical Pharmacology. 2015;71(2):183-190.
doi:10.1007/s00228-014-1778-7 .

Vučićević, Katarina, Jovanović, Marija, Golubović, Bojana, Vezmar-Kovačević, Sandra, Miljković, Branislava, Martinović, Žarko J., Prostran, Milica, "Nonlinear mixed effects modelling approach in investigating phenobarbital pharmacokinetic interactions in epileptic patients" in European Journal of Clinical Pharmacology, 71, no. 2 (2015):183-190,
https://doi.org/10.1007/s00228-014-1778-7 . .

TY  - CONF
AU  - Jovanović, Marija
AU  - Vučićević, Katarina
AU  - Golubović, Bojana
AU  - Vezmar-Kovačević, Sandra
AU  - Prostran, Milica
AU  - Martinović, Žarko J.
AU  - Miljković, Branislava
PY  - 2014
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/2117
PB  - Elsevier Science BV, Amsterdam
C3  - European Neuropsychopharmacology
T1  - No effect of carbamazepine daily dose on phenobarbital elimination in adult epileptic patients - population pharmacokinetic analysis
VL  - 24
IS  - Supplement 2
SP  - S645
EP  - S645
DO  - 10.1016/S0924-977X(14)71037-5
ER  - 

@conference{
author = "Jovanović, Marija and Vučićević, Katarina and Golubović, Bojana and Vezmar-Kovačević, Sandra and Prostran, Milica and Martinović, Žarko J. and Miljković, Branislava",
year = "2014",
publisher = "Elsevier Science BV, Amsterdam",
journal = "European Neuropsychopharmacology",
title = "No effect of carbamazepine daily dose on phenobarbital elimination in adult epileptic patients - population pharmacokinetic analysis",
volume = "24",
number = "Supplement 2",
pages = "S645-S645",
doi = "10.1016/S0924-977X(14)71037-5"
}

Jovanović, M., Vučićević, K., Golubović, B., Vezmar-Kovačević, S., Prostran, M., Martinović, Ž. J.,& Miljković, B.. (2014). No effect of carbamazepine daily dose on phenobarbital elimination in adult epileptic patients - population pharmacokinetic analysis. in European Neuropsychopharmacology
Elsevier Science BV, Amsterdam., 24(Supplement 2), S645-S645.
https://doi.org/10.1016/S0924-977X(14)71037-5

Jovanović M, Vučićević K, Golubović B, Vezmar-Kovačević S, Prostran M, Martinović ŽJ, Miljković B. No effect of carbamazepine daily dose on phenobarbital elimination in adult epileptic patients - population pharmacokinetic analysis. in European Neuropsychopharmacology. 2014;24(Supplement 2):S645-S645.
doi:10.1016/S0924-977X(14)71037-5 .

Jovanović, Marija, Vučićević, Katarina, Golubović, Bojana, Vezmar-Kovačević, Sandra, Prostran, Milica, Martinović, Žarko J., Miljković, Branislava, "No effect of carbamazepine daily dose on phenobarbital elimination in adult epileptic patients - population pharmacokinetic analysis" in European Neuropsychopharmacology, 24, no. Supplement 2 (2014):S645-S645,
https://doi.org/10.1016/S0924-977X(14)71037-5 . .

TY  - JOUR
AU  - Brzaković, Branka
AU  - Vučićević, Katarina
AU  - Vezmar-Kovačević, Sandra
AU  - Miljković, Branislava
AU  - Prostran, Milica
AU  - Martinović, Žarko J.
AU  - Pokrajac, Milena
PY  - 2014
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/2183
AB  - The purpose of the study was to examine and describe adjunctive lamotrigine (LTG) pharmacokinetics in paediatric and young adult patients using a nonlinear mixed effects modelling (NONMEM) approach. The study included 53 patients (age range 3-35 years) who were concomitantly treated with carbamazepine (CBZ) and/or valproic acid (VPA). A total of 70 blood samples corresponding to trough levels were available for analysis. Data were modelled, and the final model was evaluated using NONMEM and auxiliary software tools. The final LTG population model included the effects of concomitant drugs and patient's weight (WT) which stratified the population into three groups: a parts per thousand currency sign25 kg, > 25 to  lt  60 kg and a parts per thousand yen60 kg. Based on the final model, the estimated LTG oral clearance (CL/F) for a typical patient weighing a parts per thousand currency sign25 kg, > 25 to  lt  60 kg or a parts per thousand yen60 kg who was concomitantly treated with CBZ was estimated to be 3.28, 4.23, or 7.15 l/h, respectively. If a patient was concomitantly treated with CBZ + VPA, the CL/F decreased on average by 69.5 % relative to LTG + CBZ co-therapy. VPA was found to decrease the LTG CL/F by 87.6 % compared to co-therapy with only CBZ. The LTG population pharmacokinetic model developed in this study may be a reliable method for individualising the LTG dosing regimen in paediatric and young adult patients on combination therapy during therapeutic drug monitoring.
PB  - Springer Heidelberg, Heidelberg
T2  - European Journal of Clinical Pharmacology
T1  - Pharmacokinetics of lamotrigine in paediatric and young adult epileptic patients-nonlinear mixed effects modelling approach
VL  - 70
IS  - 2
SP  - 179
EP  - 185
DO  - 10.1007/s00228-013-1606-5
ER  - 

@article{
author = "Brzaković, Branka and Vučićević, Katarina and Vezmar-Kovačević, Sandra and Miljković, Branislava and Prostran, Milica and Martinović, Žarko J. and Pokrajac, Milena",
year = "2014",
abstract = "The purpose of the study was to examine and describe adjunctive lamotrigine (LTG) pharmacokinetics in paediatric and young adult patients using a nonlinear mixed effects modelling (NONMEM) approach. The study included 53 patients (age range 3-35 years) who were concomitantly treated with carbamazepine (CBZ) and/or valproic acid (VPA). A total of 70 blood samples corresponding to trough levels were available for analysis. Data were modelled, and the final model was evaluated using NONMEM and auxiliary software tools. The final LTG population model included the effects of concomitant drugs and patient's weight (WT) which stratified the population into three groups: a parts per thousand currency sign25 kg, > 25 to  lt  60 kg and a parts per thousand yen60 kg. Based on the final model, the estimated LTG oral clearance (CL/F) for a typical patient weighing a parts per thousand currency sign25 kg, > 25 to  lt  60 kg or a parts per thousand yen60 kg who was concomitantly treated with CBZ was estimated to be 3.28, 4.23, or 7.15 l/h, respectively. If a patient was concomitantly treated with CBZ + VPA, the CL/F decreased on average by 69.5 % relative to LTG + CBZ co-therapy. VPA was found to decrease the LTG CL/F by 87.6 % compared to co-therapy with only CBZ. The LTG population pharmacokinetic model developed in this study may be a reliable method for individualising the LTG dosing regimen in paediatric and young adult patients on combination therapy during therapeutic drug monitoring.",
publisher = "Springer Heidelberg, Heidelberg",
journal = "European Journal of Clinical Pharmacology",
title = "Pharmacokinetics of lamotrigine in paediatric and young adult epileptic patients-nonlinear mixed effects modelling approach",
volume = "70",
number = "2",
pages = "179-185",
doi = "10.1007/s00228-013-1606-5"
}

Brzaković, B., Vučićević, K., Vezmar-Kovačević, S., Miljković, B., Prostran, M., Martinović, Ž. J.,& Pokrajac, M.. (2014). Pharmacokinetics of lamotrigine in paediatric and young adult epileptic patients-nonlinear mixed effects modelling approach. in European Journal of Clinical Pharmacology
Springer Heidelberg, Heidelberg., 70(2), 179-185.
https://doi.org/10.1007/s00228-013-1606-5

Brzaković B, Vučićević K, Vezmar-Kovačević S, Miljković B, Prostran M, Martinović ŽJ, Pokrajac M. Pharmacokinetics of lamotrigine in paediatric and young adult epileptic patients-nonlinear mixed effects modelling approach. in European Journal of Clinical Pharmacology. 2014;70(2):179-185.
doi:10.1007/s00228-013-1606-5 .

Brzaković, Branka, Vučićević, Katarina, Vezmar-Kovačević, Sandra, Miljković, Branislava, Prostran, Milica, Martinović, Žarko J., Pokrajac, Milena, "Pharmacokinetics of lamotrigine in paediatric and young adult epileptic patients-nonlinear mixed effects modelling approach" in European Journal of Clinical Pharmacology, 70, no. 2 (2014):179-185,
https://doi.org/10.1007/s00228-013-1606-5 . .

TY  - JOUR
AU  - Brzaković, B. B.
AU  - Vezmar-Kovačević, Sandra
AU  - Vučićević, Katarina
AU  - Miljković, Branislava
AU  - Martinović, Žarko J.
AU  - Pokrajac, Milena
AU  - Prostran, Milica
PY  - 2012
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/1634
AB  - What is known and Objective: Lamotrigine metabolism may be substantially altered with concomitant administration of valproic acid and/or carbamazepine. Such alterations may require the adjustment of lamotrigine dose to ensure optimal treatment efficacy and safety. Methods: The extent of lamotrigine interactions was investigated dependent on age, gender, weight and dose of concomitant carbamazepine and/or valproic acid in 65 patients with epilepsy. Lamotrigine plasma steady-state oral clearance (CLss/F) and area under the curve (AUCss) were calculated from the dose of drug, average steady-state concentration (Css) and interval of administration. Multiple regression analysis was used for the identification and quantification of factors that influenced lamotrigine pharmacokinetics. Results and Discussion: Age and dose of carbamazepine and valproic acid had significant influence on lamotrigine CLss/F and AUCss. Carbamazepine was associated with a dose-dependent increase and valproic acid with a dose-dependent decrease of lamotrigine metabolism rate. The effect of carbamazepine was more pronounced. Younger patients were expected to metabolize lamotrigine more rapidly whereas overweight patients may be less susceptible to interactions. Gender had no influence on lamotrigine pharmacokinetics. What is new and Conclusion: The efficacy and safety of lamotrigine may be altered by concomitant administration of carbamazepine and valproic acid. The models developed may be useful for estimating doses of lamotrigine for individual patients to minimize clinically significant interactions. Therapeutic monitoring is advisable when those drugs are used concomitantly.
PB  - Wiley-Blackwell, Hoboken
T2  - Journal of Clinical Pharmacy and Therapeutics
T1  - Impact of age, weight and concomitant treatment on lamotrigine pharmacokinetics
VL  - 37
IS  - 6
SP  - 693
EP  - 697
DO  - 10.1111/j.1365-2710.2012.01351.x
ER  - 

@article{
author = "Brzaković, B. B. and Vezmar-Kovačević, Sandra and Vučićević, Katarina and Miljković, Branislava and Martinović, Žarko J. and Pokrajac, Milena and Prostran, Milica",
year = "2012",
abstract = "What is known and Objective: Lamotrigine metabolism may be substantially altered with concomitant administration of valproic acid and/or carbamazepine. Such alterations may require the adjustment of lamotrigine dose to ensure optimal treatment efficacy and safety. Methods: The extent of lamotrigine interactions was investigated dependent on age, gender, weight and dose of concomitant carbamazepine and/or valproic acid in 65 patients with epilepsy. Lamotrigine plasma steady-state oral clearance (CLss/F) and area under the curve (AUCss) were calculated from the dose of drug, average steady-state concentration (Css) and interval of administration. Multiple regression analysis was used for the identification and quantification of factors that influenced lamotrigine pharmacokinetics. Results and Discussion: Age and dose of carbamazepine and valproic acid had significant influence on lamotrigine CLss/F and AUCss. Carbamazepine was associated with a dose-dependent increase and valproic acid with a dose-dependent decrease of lamotrigine metabolism rate. The effect of carbamazepine was more pronounced. Younger patients were expected to metabolize lamotrigine more rapidly whereas overweight patients may be less susceptible to interactions. Gender had no influence on lamotrigine pharmacokinetics. What is new and Conclusion: The efficacy and safety of lamotrigine may be altered by concomitant administration of carbamazepine and valproic acid. The models developed may be useful for estimating doses of lamotrigine for individual patients to minimize clinically significant interactions. Therapeutic monitoring is advisable when those drugs are used concomitantly.",
publisher = "Wiley-Blackwell, Hoboken",
journal = "Journal of Clinical Pharmacy and Therapeutics",
title = "Impact of age, weight and concomitant treatment on lamotrigine pharmacokinetics",
volume = "37",
number = "6",
pages = "693-697",
doi = "10.1111/j.1365-2710.2012.01351.x"
}

Brzaković, B. B., Vezmar-Kovačević, S., Vučićević, K., Miljković, B., Martinović, Ž. J., Pokrajac, M.,& Prostran, M.. (2012). Impact of age, weight and concomitant treatment on lamotrigine pharmacokinetics. in Journal of Clinical Pharmacy and Therapeutics
Wiley-Blackwell, Hoboken., 37(6), 693-697.
https://doi.org/10.1111/j.1365-2710.2012.01351.x

Brzaković BB, Vezmar-Kovačević S, Vučićević K, Miljković B, Martinović ŽJ, Pokrajac M, Prostran M. Impact of age, weight and concomitant treatment on lamotrigine pharmacokinetics. in Journal of Clinical Pharmacy and Therapeutics. 2012;37(6):693-697.
doi:10.1111/j.1365-2710.2012.01351.x .

Brzaković, B. B., Vezmar-Kovačević, Sandra, Vučićević, Katarina, Miljković, Branislava, Martinović, Žarko J., Pokrajac, Milena, Prostran, Milica, "Impact of age, weight and concomitant treatment on lamotrigine pharmacokinetics" in Journal of Clinical Pharmacy and Therapeutics, 37, no. 6 (2012):693-697,
https://doi.org/10.1111/j.1365-2710.2012.01351.x . .

TY  - CONF
AU  - Vučićević, Katarina
AU  - Miljković, Branislava
AU  - Pokrajac, Milena
AU  - Prostran, Milica
AU  - Martinović, Žarko J.
AU  - Veličković, Ružica
AU  - Grabnar, Iztok
PY  - 2010
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/1348
PB  - Elsevier Science BV, Amsterdam
C3  - European Neuropsychopharmacology
T1  - Assessment of benzodiazepines-valproic acid pharmacokinetic interaction in adult epileptic patients: population approach
VL  - 20
IS  - Supplement 3
SP  - S247
EP  - S248
DO  - 10.1016/S0924-977X(10)70310-2
ER  - 

@conference{
author = "Vučićević, Katarina and Miljković, Branislava and Pokrajac, Milena and Prostran, Milica and Martinović, Žarko J. and Veličković, Ružica and Grabnar, Iztok",
year = "2010",
publisher = "Elsevier Science BV, Amsterdam",
journal = "European Neuropsychopharmacology",
title = "Assessment of benzodiazepines-valproic acid pharmacokinetic interaction in adult epileptic patients: population approach",
volume = "20",
number = "Supplement 3",
pages = "S247-S248",
doi = "10.1016/S0924-977X(10)70310-2"
}

Vučićević, K., Miljković, B., Pokrajac, M., Prostran, M., Martinović, Ž. J., Veličković, R.,& Grabnar, I.. (2010). Assessment of benzodiazepines-valproic acid pharmacokinetic interaction in adult epileptic patients: population approach. in European Neuropsychopharmacology
Elsevier Science BV, Amsterdam., 20(Supplement 3), S247-S248.
https://doi.org/10.1016/S0924-977X(10)70310-2

Vučićević K, Miljković B, Pokrajac M, Prostran M, Martinović ŽJ, Veličković R, Grabnar I. Assessment of benzodiazepines-valproic acid pharmacokinetic interaction in adult epileptic patients: population approach. in European Neuropsychopharmacology. 2010;20(Supplement 3):S247-S248.
doi:10.1016/S0924-977X(10)70310-2 .

Vučićević, Katarina, Miljković, Branislava, Pokrajac, Milena, Prostran, Milica, Martinović, Žarko J., Veličković, Ružica, Grabnar, Iztok, "Assessment of benzodiazepines-valproic acid pharmacokinetic interaction in adult epileptic patients: population approach" in European Neuropsychopharmacology, 20, no. Supplement 3 (2010):S247-S248,
https://doi.org/10.1016/S0924-977X(10)70310-2 . .

TY  - JOUR
AU  - Vučićević, Katarina
AU  - Miljković, Branislava
AU  - Pokrajac, Milena
AU  - Prostran, Milica
AU  - Martinović, Žarko J.
AU  - Grabnar, Iztok
PY  - 2009
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/1211
AB  - Monitoring valproic acid (VPA) concentrations is especially challenging due to its highly variable pharmacokinetics (PK) and complex interactions with other antiepileptic drugs. We used sparse routine therapeutic drug monitoring data (n = 200) from 129 adults with epilepsy to develop a population PK model of VPA, and determine the factors that influence its clearance (CL/F). Patients were on mono VPA therapy, or were concomitantly treated with carbamazepine, phenobarbital, topiramate (TPR), lamotrigine or benzodiazepines. A one-compartment model with first-order absorption and elimination was used to fit the concentration-time VPA data. Estimates generated by NONMEM indicated that VPA CL/F was influenced by the patients' body weight (increases with the 0.556 exponent), VPA daily dose (if it is greater than 1000 mg/day, CL/F increases by 43%), and co-therapy with TPR (lowering CL/F for 23%). The interindividual variability in VPA CL/F was modeled with exponentional error model. The estimated coefficient of variation was 31.9%, while the residual variability was 23.8% for the proportional and 13.2 mg/l for the additive component. The model was validated in a separate set of 24 patients, and the predictive performance was evaluated, that indicated unbias and acceptable precision. This study confirms the interaction of VPA with TPR, which is presumably dependent on VPA dose.
PB  - Elsevier Science BV, Amsterdam
T2  - European Journal of Pharmaceutical Sciences
T1  - The influence of drug-drug interaction and patients' characteristics on valproic acid's clearance in adults with epilepsy using nonlinear mixed effects modeling
VL  - 38
IS  - 5
SP  - 512
EP  - 518
DO  - 10.1016/j.ejps.2009.09.017
ER  - 

@article{
author = "Vučićević, Katarina and Miljković, Branislava and Pokrajac, Milena and Prostran, Milica and Martinović, Žarko J. and Grabnar, Iztok",
year = "2009",
abstract = "Monitoring valproic acid (VPA) concentrations is especially challenging due to its highly variable pharmacokinetics (PK) and complex interactions with other antiepileptic drugs. We used sparse routine therapeutic drug monitoring data (n = 200) from 129 adults with epilepsy to develop a population PK model of VPA, and determine the factors that influence its clearance (CL/F). Patients were on mono VPA therapy, or were concomitantly treated with carbamazepine, phenobarbital, topiramate (TPR), lamotrigine or benzodiazepines. A one-compartment model with first-order absorption and elimination was used to fit the concentration-time VPA data. Estimates generated by NONMEM indicated that VPA CL/F was influenced by the patients' body weight (increases with the 0.556 exponent), VPA daily dose (if it is greater than 1000 mg/day, CL/F increases by 43%), and co-therapy with TPR (lowering CL/F for 23%). The interindividual variability in VPA CL/F was modeled with exponentional error model. The estimated coefficient of variation was 31.9%, while the residual variability was 23.8% for the proportional and 13.2 mg/l for the additive component. The model was validated in a separate set of 24 patients, and the predictive performance was evaluated, that indicated unbias and acceptable precision. This study confirms the interaction of VPA with TPR, which is presumably dependent on VPA dose.",
publisher = "Elsevier Science BV, Amsterdam",
journal = "European Journal of Pharmaceutical Sciences",
title = "The influence of drug-drug interaction and patients' characteristics on valproic acid's clearance in adults with epilepsy using nonlinear mixed effects modeling",
volume = "38",
number = "5",
pages = "512-518",
doi = "10.1016/j.ejps.2009.09.017"
}

Vučićević, K., Miljković, B., Pokrajac, M., Prostran, M., Martinović, Ž. J.,& Grabnar, I.. (2009). The influence of drug-drug interaction and patients' characteristics on valproic acid's clearance in adults with epilepsy using nonlinear mixed effects modeling. in European Journal of Pharmaceutical Sciences
Elsevier Science BV, Amsterdam., 38(5), 512-518.
https://doi.org/10.1016/j.ejps.2009.09.017

Vučićević K, Miljković B, Pokrajac M, Prostran M, Martinović ŽJ, Grabnar I. The influence of drug-drug interaction and patients' characteristics on valproic acid's clearance in adults with epilepsy using nonlinear mixed effects modeling. in European Journal of Pharmaceutical Sciences. 2009;38(5):512-518.
doi:10.1016/j.ejps.2009.09.017 .

Vučićević, Katarina, Miljković, Branislava, Pokrajac, Milena, Prostran, Milica, Martinović, Žarko J., Grabnar, Iztok, "The influence of drug-drug interaction and patients' characteristics on valproic acid's clearance in adults with epilepsy using nonlinear mixed effects modeling" in European Journal of Pharmaceutical Sciences, 38, no. 5 (2009):512-518,
https://doi.org/10.1016/j.ejps.2009.09.017 . .

TY  - CONF
AU  - Brzaković, Branka
AU  - Pokrajac, Milena
AU  - Miljković, Branislava
AU  - Martinović, Žarko J.
AU  - Veličković, Ružica
PY  - 2007
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/972
PB  - Springer, Dordrecht
C3  - Pharmacy World & Science
T1  - Correlation between dose and plasma concentrations of lamotrigine in adult patients and children with epilepsy
VL  - 29
IS  - 5
SP  - 499
EP  - 499
UR  - https://hdl.handle.net/21.15107/rcub_farfar_972
ER  - 

@conference{
author = "Brzaković, Branka and Pokrajac, Milena and Miljković, Branislava and Martinović, Žarko J. and Veličković, Ružica",
year = "2007",
publisher = "Springer, Dordrecht",
journal = "Pharmacy World & Science",
title = "Correlation between dose and plasma concentrations of lamotrigine in adult patients and children with epilepsy",
volume = "29",
number = "5",
pages = "499-499",
url = "https://hdl.handle.net/21.15107/rcub_farfar_972"
}

Brzaković, B., Pokrajac, M., Miljković, B., Martinović, Ž. J.,& Veličković, R.. (2007). Correlation between dose and plasma concentrations of lamotrigine in adult patients and children with epilepsy. in Pharmacy World & Science
Springer, Dordrecht., 29(5), 499-499.
https://hdl.handle.net/21.15107/rcub_farfar_972

Brzaković B, Pokrajac M, Miljković B, Martinović ŽJ, Veličković R. Correlation between dose and plasma concentrations of lamotrigine in adult patients and children with epilepsy. in Pharmacy World & Science. 2007;29(5):499-499.
https://hdl.handle.net/21.15107/rcub_farfar_972 .

Brzaković, Branka, Pokrajac, Milena, Miljković, Branislava, Martinović, Žarko J., Veličković, Ružica, "Correlation between dose and plasma concentrations of lamotrigine in adult patients and children with epilepsy" in Pharmacy World & Science, 29, no. 5 (2007):499-499,
https://hdl.handle.net/21.15107/rcub_farfar_972 .

TY  - CONF
AU  - Brzaković, Branka
AU  - Pokrajac, Milena
AU  - Martinović, Žarko J.
AU  - Veličković, Ružica
AU  - Miljković, Branislava
AU  - Varagić, V.M.
PY  - 2002
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/363
PB  - Savez farmaceutskih udruženja Srbije, Beograd
C3  - Arhiv za farmaciju
T1  - Disposition of Lamotrigine in children with epilepsy receiving politherapy
T1  - Dispozicija Lamotrigina u kombinovano terapiji dece sa epilepsijom
VL  - 52
IS  - 4
SP  - 668
EP  - 669
UR  - https://hdl.handle.net/21.15107/rcub_farfar_363
ER  - 

@conference{
author = "Brzaković, Branka and Pokrajac, Milena and Martinović, Žarko J. and Veličković, Ružica and Miljković, Branislava and Varagić, V.M.",
year = "2002",
publisher = "Savez farmaceutskih udruženja Srbije, Beograd",
journal = "Arhiv za farmaciju",
title = "Disposition of Lamotrigine in children with epilepsy receiving politherapy, Dispozicija Lamotrigina u kombinovano terapiji dece sa epilepsijom",
volume = "52",
number = "4",
pages = "668-669",
url = "https://hdl.handle.net/21.15107/rcub_farfar_363"
}

Brzaković, B., Pokrajac, M., Martinović, Ž. J., Veličković, R., Miljković, B.,& Varagić, V.M.. (2002). Disposition of Lamotrigine in children with epilepsy receiving politherapy. in Arhiv za farmaciju
Savez farmaceutskih udruženja Srbije, Beograd., 52(4), 668-669.
https://hdl.handle.net/21.15107/rcub_farfar_363

Brzaković B, Pokrajac M, Martinović ŽJ, Veličković R, Miljković B, Varagić V. Disposition of Lamotrigine in children with epilepsy receiving politherapy. in Arhiv za farmaciju. 2002;52(4):668-669.
https://hdl.handle.net/21.15107/rcub_farfar_363 .

Brzaković, Branka, Pokrajac, Milena, Martinović, Žarko J., Veličković, Ružica, Miljković, Branislava, Varagić, V.M., "Disposition of Lamotrigine in children with epilepsy receiving politherapy" in Arhiv za farmaciju, 52, no. 4 (2002):668-669,
https://hdl.handle.net/21.15107/rcub_farfar_363 .